DATA GRAPHICS | Data Byte
New modalities flood the EGFR pipeline
Bispecifics, ADCs and more compete to become the next-generation of EGFR-targeting agents
October 24, 2024 6:31 PM UTC
A 20-year evolution of small molecule and antibody designs has defined the drug development story for the cancer target EGFR, but new modality therapies will feature in the target’s next chapter.
Emerging resistance is where the traditional modalities continue to fall short, and that’s what many new modality therapies are designed to prevent, or at least reduce. ...
BCIQ Company Profiles